CVR Medical Corp. announces its intention to grant a patent
Vancouver, British Columbia – (Newsfile Corp. – November 2, 2021) – CVR Medical Corp. (TSXV: CVM) (OTC Pink: CRRVF) (“Medical CVR“or the”Society” Where “we“) A listed, US-based Canadian healthcare company in the medical device market is pleased to announce its intention to grant a patent.
CVR Medical is pleased to announce that it has received a submission under Rule 71 (3) from the European Patent Office (the “EPO”) for its sensor, detection pad and network of sensors for the detection of infrasonic acoustic signals informing CVR of the intention to grant a patent based on the pursued application. This is the first patent application authorized for CVR Medical at the EPO and is an integral part of CVR’s intellectual property portfolio with an anticipated priority date of June 24, 2010. The application, which was continued under request no. 11754558.2 relates to a sensor, sensor pad, and sensor array for detecting infrasonic signals in a living organism and can be used to detect levels of stenosis, occlusion, or aneurysm in arteries. CVR Medical will post an update on patents and clinical developments as we move forward.
About CVR Medical
CVR Medical Corp. is a healthcare company operating in the medical device industry focused on the commercialization of its proprietary and revolutionary carotid stenosis analysis device (“CSSThe CSS is a diagnostic tool that encompasses the analysis technology of subsonic, infrasonic and low frequency sound waves. The CSS is a patented device designed to detect and measure carotid artery stenosis. CVR Medical are listed on the OTCQX under the symbol “CRRVF”. The Company is listed for trading under the symbol “CVM”. Additional information regarding the Company can be found in our recent filings with SEDAR as well as information maintained on our website at www.cvrmed.com.
ON BEHALF OF THE BOARD:
(signed) Paul Blunden, MD
President and Director, Interim CFO
For more information contact:
Paul Blunden, MD, President / Director, Interim CFO
Email: [email protected]
This press release contains forward-looking information which involves various risks and uncertainties regarding future events relating to: trading and dialogue with the Bourse, communications and negotiations with CVR Global, dialogue with certain advisers, the proposed restructuring, the contract license, review, certain corporate and securities law requirements, capital raising and potential litigation. Such statements are subject to risks and uncertainties which may cause actual results, performance or developments to differ materially from those contained in the statements and are not guarantees of the future performance of the Company. No assurance can be given that any of the events anticipated by forward-looking statements will occur or, if they occur, what benefits the Company will derive from them. These forward-looking statements reflect the current opinions of management and are based on certain expectations, estimates and assumptions which may prove to be incorrect. A number of risks and uncertainties could cause our actual results to differ materially from those expressed or implied by forward-looking statements, including: (1) a material failure or setback of the Company meeting the other conditions described by the TSX Venture Exchange; (2) a failure of the Company to raise sufficient capital to revive the Company; (3) an inability to complete the proposed restructuring with CVR Global: (4) a slowdown in general economic conditions in North America and internationally; (5) the inherent uncertainties and speculative nature associated with the commercialization of technology and the practice of medicine; (6) a change in health regulations; (7) any number of events or causes that may delay or stop the marketing and development of the CSS Device; (8) the risk that the Company will not execute its business plan; (9) the risk of litigation between the Company and certain shareholders and the risk of litigation in general; (10) an inability to retain key employees; (11) an inability to finance operations and growth; (12) compliance with certain requirements of company and securities laws; and (13) other factors beyond the control of the Company. These forward-looking statements are made as of the date of this press release and, except as required by law, the Company assumes no obligation to update these forward-looking statements or to update the reasons why actual results differ. of those projected in the forward-looking statements.
THE TSX VENTURE EXCHANGE INC. HAS NEITHER APPROVED OR REJECTED THE CONTENT OF THIS RELEASE. NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATORY SERVICES PROVIDER (AS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS COMMUNICATION.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/101692